Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he insists it will actually ship products.

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Despite decades of research showing that traditional interviews are only moderately reliable predictors of performance, organizations continue to rely on them heavily. In fact, the typical interview ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

The consensus mark for RXRX's Q4 loss and sales are pinned at 28 cents per share and $25.5M, respectively. In late 2025, RXRX highlighted REC-4881 data showing rapid, durable polyp reductions in FAP ...

There's one job interview question that you can almost guarantee hiring managers will ask that many people still struggle to answer. That's because there really is no clear angle. Still, if you're ...

Four New York Times reporters pressed Mr. Trump about a range of topics in a nearly two-hour interview. Here is a transcript of their conversation. President Trump spoke to four New York Times ...

This is an edited transcript of “The Ezra Klein Show.” You can listen to the episode wherever you get your podcasts. At the beginning of the year, I always like to do a couple of episodes on things ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...